Inversago Pharma’s CEO François Ravenelle will attend Biotech Showcase to be held January 13-15, 2020 in San Francisco, CA. Come and meet with us!
Inversago Pharma Strengthens its Board of Directors with the Appointment of Two Industry Experts
MONTREAL (CANADA) – 17 October 2019 – Today Inversago Pharma Inc., a preclinical-stage biotech company developing novel CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of two seasoned pharma executives in line with the Company’s aim to attract first-class industry leaders for their guidance and expertise.
Inversago Pharma Strengthens its Clinical Leadership Team
MONTREAL (CANADA) – 25 September 2019 – Today Inversago Pharma Inc., a preclinical-stage biotech company developing new CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of Dr. Caroline Fradette as Vice-President, Clinical Research.
2019 PWS Research Symposium, Oct. 3-4 – Inversago Presentation Details
Safety Assessment in Non-Human Primates of New Cannabinoid-1 Receptor Blockers to Treat Hyperphagia, Obesity and Related Metabolic Disorders in PWS. The 2019 PWS Research Symposium is organized by the Foundation for Prader-Willi Research.